Iovance Biotherapeutics Inc
IOVA3.970USD
+0.840+26.84%
Fechamento 07/23, 16:00（ET）Cotações atrasadas em 15 min
1.33BValor de mercado
PerdaP/L TTM
Mais detalhes de Iovance Biotherapeutics Inc Empresa
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. It is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. It also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
Informações da empresa
Código da empresaIOVA
Nome da EmpresaIovance Biotherapeutics Inc
Data de listagemJun 20, 2008
Fundado em2017
CEODr. Frederick G. Vogt, J.D., Ph.D.
Número de funcionários838
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 20
Endereço825 Industrial Road
CidadeSAN CARLOS
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94070
Telefone16502607120
Sitehttps://www.iovance.com/
Código da empresaIOVA
Data de listagemJun 20, 2008
Fundado em2017
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
404.60K
+8.00%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
209.85K
+1.45%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
93.63K
+6.91%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Mr. Matthew W Rosinack
Mr. Matthew W Rosinack
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Wayne P. Rothbaum
Mr. Wayne P. Rothbaum
Independent Director
Independent Director
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
404.60K
+8.00%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
209.85K
+1.45%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
93.63K
+6.91%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
48.52M
98.37%
Rest of world
804.00K
1.63%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 20 de mai
Atualizado em: ter, 20 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.30%
MHR Fund Management LLC
7.31%
BlackRock Institutional Trust Company, N.A.
6.15%
Perceptive Advisors LLC
3.81%
Other
66.02%
Investidores
Investidores
Proporção
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.30%
MHR Fund Management LLC
7.31%
BlackRock Institutional Trust Company, N.A.
6.15%
Perceptive Advisors LLC
3.81%
Other
66.02%
Tipos de investidores
Investidores
Proporção
Investment Advisor
23.17%
Investment Advisor/Hedge Fund
20.36%
Hedge Fund
12.84%
Private Equity
11.13%
Venture Capital
8.50%
Research Firm
4.03%
Bank and Trust
0.57%
Pension Fund
0.57%
Individual Investor
0.37%
Other
18.45%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
643
273.27M
81.83%
-26.86M
2025Q1
680
275.16M
84.08%
-27.55M
2024Q4
654
278.66M
85.07%
-21.74M
2024Q3
641
272.75M
89.13%
-24.76M
2024Q2
630
269.09M
94.68%
-12.01M
2024Q1
622
253.92M
89.61%
-22.91M
2023Q4
605
240.15M
93.91%
-35.32M
2023Q3
601
248.03M
97.72%
-14.72M
2023Q2
594
232.36M
107.55%
-14.37M
2023Q1
607
232.93M
108.05%
+12.27M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Quogue Capital L.L.C.
28.07M
8.4%
--
--
Apr 17, 2025
The Vanguard Group, Inc.
27.73M
8.3%
+243.44K
+0.89%
Mar 31, 2025
MHR Fund Management LLC
24.42M
7.31%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
20.54M
6.15%
+368.21K
+1.83%
Mar 31, 2025
Perceptive Advisors LLC
12.71M
3.81%
-9.40M
-42.51%
Mar 31, 2025
State Street Global Advisors (US)
11.04M
3.31%
-1.21M
-9.86%
Mar 31, 2025
Long Focus Capital Management LLC
9.25M
2.77%
+4.12M
+80.24%
Mar 31, 2025
Hood River Capital Management LLC
9.22M
2.76%
+224.47K
+2.50%
Mar 31, 2025
Soleus Capital Management, L.P.
7.79M
2.33%
+1.23M
+18.67%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.97M
1.79%
+96.88K
+1.65%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
Virtus LifeSci Biotech Products ETF
1.48%
iShares Genomics Immunology and Healthcare ETF
1.06%
WisdomTree BioRevolution Fund
0.53%
SPDR S&P Biotech ETF
0.13%
Direxion Daily S&P Biotech Bull 3X Shares
0.11%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.05%
Strive Small-Cap ETF
0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.03%
Ver Mais
Virtus LifeSci Biotech Products ETF
Proporção1.48%
iShares Genomics Immunology and Healthcare ETF
Proporção1.06%
WisdomTree BioRevolution Fund
Proporção0.53%
SPDR S&P Biotech ETF
Proporção0.13%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.11%
ProShares Ultra Nasdaq Biotechnology
Proporção0.07%
Invesco Nasdaq Biotechnology ETF
Proporção0.06%
iShares Biotechnology ETF
Proporção0.05%
Strive Small-Cap ETF
Proporção0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proporção0.03%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
